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ABSTRACT
Introduction The epidemiology of inflammatory bowel 
disease (IBD) in sub- Saharan Africa is poorly documented. 
We have started a registry to determine the burden, 
phenotype, risk factors, disease course and outcomes of 
IBD in Zimbabwe.
Methods and analysis A prospective observational 
registry with a nested case–control study has been 
established at a tertiary hospital in Harare, Zimbabwe. 
The registry is recruiting confirmed IBD cases from 
the hospital, and other facilities throughout Zimbabwe. 
Demographic and clinical data are obtained at baseline, 6 
months and annually. Two age and sex- matched non- IBD 
controls per case are recruited—a sibling or second- 
degree relative, and a randomly selected individual 
from the same neighbourhood. Cases and controls are 
interviewed for potential risk factors of IBD, and dietary 
intake using a food frequency questionnaire. Stool is 
collected for 16S rRNA- based microbiota profiling, and 
along with germline DNA from peripheral blood, is being 
biobanked. The estimated sample size is 86 cases and 172 
controls, and the overall registry is anticipated to run for at 
least 5 years. Descriptive statistics will be used to describe 
the demographic and phenotypic characteristics of IBD, 
and incidence and prevalence will be estimated for Harare. 
Risk factors for IBD will be analysed using conditional 
logistic regression. For microbial analysis, alpha diversity 
and beta diversity will be compared between cases and 
controls, and between IBD phenotypes. Mann- Whitney 
U tests for alpha diversity and Adonis (Permutational 
Multivariate Analysis of Variance) for beta diversity will be 
computed.
Ethics and dissemination Ethical approval has been 
obtained from the Parirenyatwa Hospital’s and University 
of Zimbabwe’s research ethics committee and the Medical 
Research Council of Zimbabwe. Findings will be discussed 
with patients, and the Zimbabwean Ministry of Health. 
Results will be presented at scientific meetings, published 
in peer reviewed journals, and on social media.
Trial registration number NCT04178408.
INTRODUCTION
Inflammatory bowel disease (IBD) is consid-
ered mostly a disease of high- income 
countries, and is reportedly rare in sub- 
Saharan Africa.1 However, many countries in 
sub- Saharan Africa are experiencing a rapid 
increase in diseases traditionally associated 
with westernisation, particularly, diabetes 
mellitus and obesity.2 3 Furthermore, the inci-
dence of other large bowel diseases, which 
were previously considered rare, such as 
colorectal cancer, is increasing.4 Thus, it is 
reasonable to expect that the incidence of 
IBD could also be on the rise.
However, there is limited data on the 
burden of IBD in sub- Saharan Africa. Though 
relatively uncommon, ulcerative colitis is 
believed to be the predominant phenotype, 
while Crohn’s disease is rarely diagnosed.5 
This is consistent with historical accounts of 
IBD in industrialised countries, which suggest 
that ulcerative colitis came to the fore before 
Crohn’s disease.6 The earlier increase in 
incidence of ulcerative colitis has also been 
described in the newly industrialised coun-
tries of Asia and South America.6 However, 
the situation in sub- Saharan Africa is mostly 
speculative, and the precise epidemiology, 
phenotype, course and associated risk factors 
have not been comprehensively studied.
Strengths and limitations of this study
 ► Research in a unique, under- studied population at 
an early stage of the IBD epidemic.
 ► The study uses contemporary microbiota analysis 
techniques to investigate determinants of IBD phe-
notype in an African population.
 ► The study includes a control group, addressing a de-
ficiency of most registry- based studies.
 ► Potential challenge in achieving the desired sample 
size as IBD is potentially rare, and underdiagnosed 
in this population.
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Therefore, we are establishing a prospective registry 
in Zimbabwe to describe the phenotype, disease course 
and outcomes of IBD in a population in sub- Saharan 
Africa. Furthermore, a nested case–control study will 
be performed to establish the risk factors of IBD in this 
population. This registry offers a unique opportunity to 
study the evolution of a potentially early epidemic of IBD 
using powerful modern techniques that were not avail-
able at a similar stage of the epidemic in Europe and 
North America.
OBJECTIVES
The aim of this study is to establish a prospective registry 
of IBD registry at a tertiary care hospital in Harare, 
Zimbabwe. The database will be used to: (1) describe 
the demographic and phenotypic characteristics of IBD 
in the Zimbabwean population, (2) estimate the inci-
dence, and prevalence of IBD in Harare, (3) determine 
the risk factors of IBD among Zimbabweans, (4) describe 
the microbial networks associated with IBD, and disease 
phenotype in this African population and (5) establish 
a biobank with faecal samples, intestinal biopsies and 
germline DNA for subsequent research on the aetiology, 
and evolution of IBD in an African population at an early 
stage of the potential IBD epidemic.
METHODS AND ANALYSIS
Study design
This is a prospective observational registry, with a nested 
case–control study. The registry will be based in Harare, 
Zimbabwe, but recruitment will be open to patients from 
across the country. The nested case–control study will 
enable the registry to have a control group.
Study population
The registry will be based at the gastrointestinal clinical 
at Parirenyatwa Hospital in Harare, Zimbabwe. Pariren-
yatwa Hospital is one of the two teaching hospitals of 
the University of Zimbabwe, and functions as a tertiary 
referral centre for the northern two- thirds of the country, 
and a secondary level hospital for Harare. The gastroin-
testinal clinic at Parirenyatwa Hospital was established in 
January 2018, after a hiatus of more than 20 years. It is 
the only dedicated gastroenterology clinic in the public 
sector in Zimbabwe. Although the registry will be based 
at the gastrointestinal clinic, patients from other hospi-
tals throughout the country, including private institutions 
and medical practices, will be eligible for recruitment. It 
is hoped that this will facilitate the provision of specialist 
gastroenterology services across the country, particularly 
for suspected cases of IBD. As of March 2020, Zimbabwe, 
with 14 million people, has only three practising gastro-
enterologists, all of them in Harare.
A nested case–control study will also be performed 
with the aim of determining the risk factors of IBD. Two 
controls will be recruited for each case. These will be 
either a sibling for each case or second- degree relative 
of a similar age (±5 years), and an individual from the 
same neighbourhood, matched for age (±5 years) and for 
gender. Recruiting relatives should be quite feasible in 
Zimbabwe, as the extended family structure is intact, and 
considered as important as the nuclear family.
Eligibility criteria
Any patient, of any age with confirmed IBD in Zimbabwe, 
with disease duration of at least 3 months will be eligible 
for enrolment into the registry. The diagnosis will require 
concurrence of two gastroenterologists, and pathology 
slides will be independently reviewed at the University of 
Bern, Switzerland. The case–control study will be restricted 
to adult cases; thus, all the corresponding controls will be 
older than 18 years of age. These controls will be a sibling 
or second- degree relative, and a resident in the same 
neighbourhood of a similar age (±5 years), and gender. 
All persons with unexplained gastrointestinal symptoms, 
including diarrhoea, vomiting, chronic abdominal pain, 
weight loss, rectal bleeding and recent change in bowel 
habits, will be excluded as controls. Unexplained major 
gastrointestinal surgery in the past will be an exclusion 
criterion, to avoid inadvertently, including a previously 
undiagnosed case of IBD as a control. All potential 
controls will have a baseline calprotectin, and those with 
a sustained level >200 mg/kg will be screened for IBD. 
If uncertainly remains about whether they actually have 
IBD, they will be excluded from the study.
Study procedures
Patients with IBD will be approached during routine visits 
to the gastroenterology clinic, and invited to participate. 
Clinicians in other hospitals and in private practice will 
also be informed about the registry and encouraged to 
refer patients for recruitment. Information about the 
registry will be disseminated to gastroenterologists, physi-
cians, surgeons, general practitioners and pathologists 
around the country using various channels, particularly, 
meetings of various professional associations, and appro-
priate professional social media groups. Both incident 
and prevalent cases will be considered for enrolment.
After informed consent, demographic and clinical 
data will be obtained for all cases using standardised 
case report forms at baseline, after 6 months and annu-
ally thereafter. A stool smear will be evaluated for para-
sites. Concurrently, two healthy controls per case will be 
recruited for a nested case–control study. The controls 
will be the first consenting sibling nearest in age to the 
case. If there is no appropriate sibling, a second- degree 
relative meeting the eligibility criteria will be invited to 
participate. The neighbourhood control will be randomly 
selected from the same local government ward as the 
corresponding case, by screening from door to door until 
an eligible individual is encountered. Care will be taken 
to ensure confidentiality in this process.
Both cases and controls will be interviewed using a 
questionnaire for risk factors of IBD, adapted from the 
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International Organisation for the study of Inflamma-
tory Bowel Disease (online supplemental file A).7–9 The 
adapted questionnaire takes into account factors unique 
to sub- Saharan Africa, such as the high burden of infec-
tious diseases, including HIV and tuberculosis (TB), and 
cultural factors. Dietary factors will be assessed in both 
cases and controls using a validated semi- quantitative 
food frequency questionnaire (online supplemental 
file B).10 11 Inflammation will be confirmed in cases, or 
excluded in controls using calprotectin measurements, 
and clinical evaluation. Whenever necessary, tissue slides 
from the various pathology laboratories will be reviewed 
by a single study pathologist (RM- M), and all slides will 
undergo a blinded review at the University of Bern (AB). 
The diagnosis of IBD will require the concurrence of two 
gastroenterologists in all cases (LK, WFM and IG). Micro-
biota profiling of cases and controls will be carried out at 
the University of Bern using the Ion Torrent PGM plat-
form in which V5–V6 region of bacterial 16S rRNA will 
be sequenced. A subset of samples will be sequenced on 
the Illumina platform for deeper microbiota resolution. 
In parallel, the absolute number of bacteria per gram 
of faecal samples will be assessed using flow cytometry. 
Serial stool specimens, and germline DNA from periph-
eral blood in both cases and controls will be biobanked 
at −80°C in the Department of Medicine, University of 
Zimbabwe.
Study factors
The following parameters will be collected from the 
participants in this study:
 ► Demographic data (age, gender, ethnicity, etc).
 ► For cases only:
 – clinical data, including age at diagnosis, disease 
phenotype (Crohn’s disease vs ulcerative colitis, 
location and behaviour) and other clinical, endo-
scopic, histological and radiographic features.
 – Current and previous treatment, including surgery.
 – Assessment of disease activity (Modified Truelove 
and Witts Activity Index and Harvey Bradshaw 
Index) at least yearly. Intermittent flares or IBD- 
related hospitalisations will be recorded.
 – Laboratory values: we aim for annual calprotectin 
measurements in all cases.
 – Long- term effects of IBD on health of participants 
(eg, comorbidities, malignancies, osteoporosis, 
pain, psychiatric comorbidities, etc).
 ► HIV status.
 ► Medical history.
 ► Current and previous TB status (a WHO TB screening 
tool will be administered to all participants). We 
recognise that intestinal TB and Crohn’s disease can 
be virtually indistinguishable at times and it is the 
policy of our unit to start TB treatment before starting 
any immunosuppressive medication in such cases.
 ► Family history of IBD.
 ► Socioeconomic data—income, education and 
occupation.
 ► Data on common environmental risk factors of IBD, 
including nutrition, body mass index, smoking history, 
breastfeeding, exposure to mass drug campaigns in 
childhood, family size and various markers of sanita-
tion and hygiene.
 ► Migration history (rural to urban, Zimbabwe to other 
countries).
Biobanking
Annual stool samples, germline DNA and urine specimens 
will be collected and stored at −80°C in the Department 
of Medicine, University of Zimbabwe, for future studies. 
Broad consent will be obtained from all participants, and 
this has already been approved by relevant ethical review 
committees.12
Statistical plan
The sample size was calculated for the nested case–control 
study as the registry will mainly generate descriptive data. 
Exposure to farm animals was taken as a proxy for risk 
factors for IBD. An inverse relationship between exposure 
to farm animals and IBD has been previously demonstrated 
in an umbrella review of meta- analyses of environmental 
risk factors (OR: 0.44; 95% CI: 0.14‒0.74).13 According to 
the Zimbabwe Health and Demographic Survey of 2015, 
66% of the population have no access to electricity, and 
we assumed that this should roughly correspond to the 
proportion of the population living near farm animals.14 
Therefore, the estimated sample size was 86 IBD cases 
and 172 non- IBD controls, to detect such a difference 
with a χ2 test, two matched controls per case, a correla-
tion coefficient of 0.2, power 80% and two- sided alpha of 
0.05.15 The registry is expected to run indefinitely, begin-
ning March 2020, with 5 years as the absolute minimum, 
which will maximise the sample size.
Descriptive statistics, including percentages (with 95% 
CIs), mean (with SD) and median (with IQR) will be 
used to summarise data on demographic and phenotypic 
characteristics of IBD. This data will also be compared 
with the Swiss IBD cohort study.16 The incidence of 
IBD in Harare will be estimated from the number of 
new cases identified per year, and the current estimated 
population of Harare. While cases from outside Harare 
will be included in the registry, they will be excluded in 
computing the incidence and prevalence of IBD, so that 
we have a defined denominator. The numerator for the 
incidence and prevalence should become more precise as 
the registry becomes established, and recruitment from 
the population approaches saturation level. The next 
census in Zimbabwe is scheduled for 2022, and this will 
give a contemporary denominator. If this data are not 
released timeously, then projections from the last census 
in 2012 will be used.
For the case–control study, we recognise that the sibling 
control may potentially mask significant environmental 
factors. We will identify such factors by carrying out the 
statistical analyses in the following sequence: cases versus 
neighbourhood controls, cases versus sibling controls 
4 Katsidzira L, et al. BMJ Open 2020;10:e039456. doi:10.1136/bmjopen-2020-039456
Open access 
and cases versus neighbourhood and sibling controls 
combined. In all instances, cases and controls will initially 
be compared using χ2 test for categorical and t- test for 
continuous data. Univariate and multivariate logistic 
regression will be performed to determine the indepen-
dent risk factors associated with IBD in this population. 
ORs and their CIs will be computed for this purpose.
For the microbial analysis, alpha diversity (observed 
operational taxonomic units and Simpson and Shannon 
indices) and beta diversity (Bray- Curtis genus- level 
community dissimilarities) will be calculated. Mann- 
Whitney U tests for alpha diversity and Adonis (Permuta-
tional Multivariate Analysis of Variance) for beta diversity 
will be used to confirm that the strength and statistical 
significance of groups in the same distance metrics in the 
QIIME pipeline and phyloseq.17 18
Patient and public involvement
This study was partly borne out of the question the lead 
author gets from patients about whether this disease 
is common in Africa. Often, the patients with IBD in 
Zimbabwe have not met anyone else with the disease. So, 
we have had discussions at the individual patient level 
about the need for studies to document the disease in 
the population. These discussions occurred before the 
protocol was written and continued throughout the 
design phase. However, the patients were not formally 
asked about their opinions regarding various aspects of 
the study design or the burden the study will place on 
their time. There are plans to involve the patients in 
the dissemination of the results as the registry will be a 
platform to form a patient advocacy groups as this is a 
neglected disease in Zimbabwe, with very little support 
for investigations and treatment.
ETHICS AND DISSEMINATION
Ethical approval has been obtained from the Pariren-
yatwa Hospital’s and University of Zimbabwe’s joint 
research ethics committee (JREC) (JREC 159/19), and 
the Medical Research Council of Zimbabwe (MRCZ) 
(MRCZ/A/2499).
The proposed study is an observational registry, and 
poses minimal risk to participants. All data will be anony-
mised before entry into electronic databases. Broad 
consent will be obtained from participants for purposes 
of biobanking,12 and the consent process has been 
comprehensively evaluated by the ethical review commit-
tees (JREC and MRCZ). Community engagement is 
critical in this study, and on- going and discussions with 
IBD patients are underway. The findings will be dissem-
inated to patients, the major hospitals in Zimbabwe and 
the Zimbabwean Ministry of Health. There are no IBD 
patient groups in Zimbabwe at the moment, and the find-
ings will be used for advocacy, and to motivate the forma-
tion of such groups and other support services. They will 
be presented at national, and international meetings, and 
published in peer- reviewed journals, and disseminated 
using social and broadcast media.
DISCUSSION
This study is expected to provide seminal findings on 
IBD in sub- Saharan Africa, with a potential for substantial 
impact on clinical management and resource allocation 
in this population. Furthermore, the registry represents 
a unique opportunity for a prospective study in a popu-
lation where data on the burden, disease phenotype and 
outcomes of IBD are almost non- existent.
The study team and collaborating institutions have 
diverse strengths, which will enable comprehensive 
research on the disease in an under- studied population. 
It is expected that cutting- edge techniques on the inter-
actions between the microbiome and the host in IBD will 
provide unique insights on the disease evolution and the 
factors determining phenotype. Commendably, the study 
was conceptualised by the local researchers in Zimbabwe, 
a low- resource country and this will facilitate an equitable 
north–south collaborative relationship.
Furthermore, we have included a healthy control group 
from the outset, which will minimise the limitations arising 
from lack of comparison groups that are intrinsic to most 
registry- based studies. Our major concern is the possi-
bility of a slow accrual rate and ultimately a small sample 
size. The available, though limited data, suggests that IBD 
occurs infrequently in this population.5 We anticipate 
that this will be mitigated by the relatively low mortality 
associated with IBD, and the open- ended study period. 
With a low mortality, an appreciable number of cases will 
eventually accrue over time if retention mechanisms are 
robust (although slowly). Another potential limitation 
arises from referral bias. Since the registry will be hospital 
based, it is possible that a disproportionate amount of 
the severe cases will be recruited, while mild cases in the 
community may never get referred and reported. This will 
be acknowledged in discussing the results, and may affect 
descriptions of the phenotypes, and underestimate the 
incidence and prevalence of IBD in Zimbabwe. However, 
we plan to use the study to raise the awareness of IBD 
among practitioners in Zimbabwe, and the general popu-
lation, and this may reduce the impact of such referral 
bias in the long- term.
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